Related Experiment Video

Updated: Jul 17, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

Li Zhang1, Shanmei Du1, Kui Liu1

  • 1College of Medical Technology, Zibo Polytechnic University, Zibo, Shandong, China.

Frontiers in Immunology
|July 16, 2026
PubMed

Insights

Regulatory Factor X5 (RFX5) acts differently in cancer based on tumor type and immune signals. It influences tumor growth and immune response, suggesting a dual role rather than fixed oncogenic or tumor-suppressive behavior.

Area of Science:

  • Molecular biology
  • Cancer research
  • Immunology

Background:

  • Regulatory Factor X5 (RFX5) is a transcriptional regulator with context-dependent roles in cancer.
  • RFX5 influences hepatocellular carcinoma (HCC) progression via the YWHAQ-PI3K/Akt pathway.
  • In immune-inflamed tumors, RFX5 impacts antigen presentation and T-cell infiltration, affecting immune surveillance.

Purpose of the Study:

  • To propose a dual-switch framework for understanding RFX5's context-dependent functions.
  • To investigate the correlation between RFX5 expression, clinical prognosis, and response to immune checkpoint blockade (ICB).
  • To identify translational challenges in leveraging RFX5 for cancer therapy.

Main Methods:

  • Literature review and synthesis of existing data on RFX5.
  • Retrospective analysis of clinical data correlating RFX5 expression with prognosis and ICB response.
  • Hypothesis generation based on divergent roles of RFX5 in different tumor contexts.

Main Results:

  • RFX5 exhibits context-dependent functions, acting as an oncogene in HCC and influencing immune responses in other tumors.
  • Altered RFX5 expression correlates with prognosis and ICB response in specific cancer types.
  • RFX5 may serve as a reference biomarker when integrated into composite immune signatures, not as an independent predictor.

Conclusions:

  • RFX5's function is dynamically regulated by tumor lineage and microenvironment, supporting a lineage-signal dual-switch model.
  • Current evidence does not validate RFX5 as a standalone predictive biomarker for ICB.
  • Further research is needed to define cell-type-specific targets and link RFX5 activity to therapeutic vulnerabilities.
Keywords:
PI3K/Akt pathwayRFX5biomarkercancer immunitycontext-dependent functionimmune checkpoint blockadetumour-intrinsic function

More Related Videos

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...